patients attneding for surgery with no known bladder disease

those with evidence of dysfunctional voiding

Dysfunctional Voiding

Stress Incontinence, Urinary

Evelina London Children's Hosital

Case Control Study to Investigate the Use of Urethral Pressure Profile Measurement in Children

King's College London

Mirabegron 25mg will give daily at night for 12 weeks

Solifenacin Succinate 5mg will give daily at night for 12 weeks

Overactive Bladder

Mirabegron 25mg

Solifenacin Succinate 5 MG

Bangabandhu Sheikh Mujib Medical University

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Overactive bladder symptom score Patients are instructed to circle the score that best applies to their urinary condition during the past week; the overall score the sum of the four scores.
Ques-1 How many times do youtypically urinate fromwaking in the morninguntil sleeping at night? Ques 2 How many times do you typically wake up to urinate from sleeping at night until waking in the morning? Ques 3 How often do you have a sudden desire to urinate, which is difficult to defer? Ques 4. How often do you leak urine because you cannot defer the sudden desire to urinate? Total score Sum of 4 question, Maximum score 15. Reduction OABSS will calculated from baseline

Frequency of micturation will be reduced at end of treatment at 12 week calculated from before treatment.

The percentage of patients with a change from baseline to the final visit in the urgency episodes per 24 hours by 2 or greater.

Net change of the mean number of urgency incontinence episodes from baseline to the final visit

The net change of mean number of nocturia episodes per 24 hours from baselinev to the final visit

Dry mouth, constipation, blurred vision, hypertension, haedache, nasopharyngitis.
Number of participant will be developed advers effect during study period will compared between them.

Number of participant discontinue drug due to adverse effect wil compared between them

Dr. A S M Kutub Uddin Awal

Final year Resident, Department of urology

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits

Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF

Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV

Nocturia

BPH With Urinary Obstruction

Prostatism

Prostate Inflammation

Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF

Microcannula Harvest Adipose

Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF

Centricyte 1000

Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway

IV Sterile Normal Saline

Global Alliance for Regenerative Medicine-USA

Regenevita LLC

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy

Report of minor and severe adverse effects caused by the procedures

Assessment of change from baseline (0) of frequency, urgency, pain, voiding time, and flow rate during voiding

Visual Analog Pain Scale (VAS) designated as levels pain 1-10

BPH Symptom Score change from baseline use American Urological Association Symptom Score Index change from baseline using Amercian Urological Association Symptom Score Index (AUA SI)

Change from Baseline of Measured International Prostate Symptom Score (I-PPS)

Robert W. Alexander, MD, FICS

Principal Investigator, Science

Terry, Glenn C., M.D.

Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS

Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary

Lower Urinary Tract Symptoms

Voiding Dysfunction

Benign Prostate Obstruction

Detrusor Underactivity

Diagnostic test for urinary storage and voiding function

Urodynamics

Usual care

North Bristol NHS Trust

Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods

Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for Diagnosis and Management of Bladder Outlet Obstruction in Men

Primary clinical outcome: difference in lower urinary tract symptom (LUTS) between the two arms at 18 months, measured with the International Prostate Symptom Score (IPSS)

The relative proportion of men in each group having surgery up to 18 months after randomisation

Cost effectiveness from the perspectives of the Health Service, Personal Social Services and patients

Adverse events of testing and treatment (e.g. infection, urinary retention).

Measures from the International Consultation on Incontinence Questionnaires (ICIQ) regarding LUTS severity/ bother, sexual function, quality of life and satisfaction with urodynamic testing. The following will be measured at 6, 12 and 18 months; IPSS (including quality of life) ICIQ Male LUTS (ICIQ-MLUTS) ICIQ sexual function in Male LUTS (ICIQ-MLUTS-sex)

Maximum urinary flow rate (Qmax) at 18 months. In men undergoing surgery in both arms, an additional Qmax measure at 4 months after operation will be used as a quality measure for surgery.

EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). In the descriptive system, respondents rate their health 'TODAY' according to 5 dimensions (Mobility; Self-Care; Usual Activities; Pain/Discomfort; and Anxiety/Depression), with 5 levels of severity (No Problems; Slight; Moderate; Severe; and Extreme Problems). This results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). The VAS can be used as a quantitative measure of health outcome reflecting the patient's own judgement. Full details of the scoring system can be found via the EQ-5D website/user guide.

"UPSTREAM - Phase II": difference in lower urinary tract symptom (LUTS)

"UPSTREAM - Phase II": The relative proportion of men in each group having surgery up to 5 years after randomisation

"UPSTREAM - Phase II": ICIQ Male LUTS (ICIQ-MLUTS); questionnaire evaluating MLUTS and impact on quality of life. 13 items, Scoring: 0-20 voiding symptoms subscale 0-24 incontinence symptoms subscale. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient. See https://iciq.net for further information.

"UPSTREAM - Phase II":ICIQ sexual function in Male LUTS (ICIQ-MLUTS-sex). Patient-complete questionnaire for evaluation of male sexual function associated with their MLUTS and impact of quality of life. 4 items, scoring: 0-12 overall score with greater values indicating increasing problems with sexual matters. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient. See https://iciq.net for further information.

"UPSTREAM - Phase II": International Prostate Symptom Score (IPSS) including QoL question. The IPSS is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).

"UPSTREAM - Phase II": EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). In the descriptive system, respondents rate their health 'TODAY' according to 5 dimensions (Mobility; Self-Care; Usual Activities; Pain/Discomfort; and Anxiety/Depression), with 5 levels of severity (No Problems; Slight; Moderate; Severe; and Extreme Problems). This results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). The VAS can be used as a quantitative measure of health outcome reflecting the patient's own judgement. Full details of the scoring system can be found via the EQ-5D website/user guide.

urinary bladder neck obstruction/asthenia

Case Control Study to Investigate the Use of Urethral Pressure Profile Measurement in Children

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu